Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Total Current Liabilities (2016 - 2025)

Guided Therapeutics' Total Current Liabilities history spans 16 years, with the latest figure at $6.5 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 7.39% year-over-year to $6.5 million; the TTM value through Sep 2025 reached $6.5 million, up 7.39%, while the annual FY2024 figure was $6.2 million, 27.99% up from the prior year.
  • Total Current Liabilities for Q3 2025 was $6.5 million at Guided Therapeutics, up from $6.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $9.2 million in Q1 2021 and bottomed at $4.0 million in Q1 2023.
  • The 5-year median for Total Current Liabilities is $5.7 million (2021), against an average of $5.7 million.
  • The largest annual shift saw Total Current Liabilities tumbled 40.96% in 2022 before it soared 33.45% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $5.7 million in 2021, then fell by 14.49% to $4.9 million in 2022, then decreased by 1.23% to $4.8 million in 2023, then increased by 27.99% to $6.2 million in 2024, then rose by 5.12% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Total Current Liabilities are $6.5 million (Q3 2025), $6.4 million (Q2 2025), and $5.9 million (Q1 2025).